放射性配体治疗中肿瘤响应的建模与预测
本研究基于治疗前PET/CT测量和生理药代动力学/药效学(PBPK/PD)模型,以177Lu标记的PSMA I&T为例,回顾性分析13例转移性去势抵抗性前列腺癌患者,预测放射性配体治疗后PSMA阳性肿瘤体积。治疗后6周预测与实测肿瘤体积的相对偏差为1%±40%(排除1例PSA阴性患者),PSA阳性患者放射敏感性为0.0172±0.0084 Gy⁻¹。作者认为该方法是首次仅用PET/CT和建模预测RLT后肿瘤体积的尝试,内部验证显示可行且精度可接受,方法改进与外部验证正在进行中。
要点
- 基于治疗前PET/CT和PBPK/PD建模预测177Lu-PSMA I&T RLT后6周PSMA阳性肿瘤体积。
- 13例mCRPC患者回顾性分析,预测与实测肿瘤体积相对偏差1%±40%(排除1例PSA阴性患者)。
- PSA阳性患者放射敏感性为0.0172±0.0084 Gy⁻¹,内部Jackknife验证显示可行且精度可接受。
核心结论
- 据作者所知,所提方法是首次仅使用PET/CT和建模方法预测RLT后PSMA阳性肿瘤体积的尝试。
- 内部验证显示该方法可行且精度可接受,方法的改进和模型的外部验证正在进行中。
研究设计与样本
- 回顾性分析13例转移性去势抵抗性前列腺癌患者的数据。
- 将新近开发的177Lu-PSMA I&T RLT的PBPK模型扩展以纳入肿瘤指数生长和照射所致减少(线性二次模型)。
- 在贝叶斯框架中同时拟合药代动力学/药效学参数至PET/CT活度浓度、平面闪烁显像数据及治疗前和治疗后6周的肿瘤体积。
- 采用留一法Jackknife方法进行验证。
- 基于治疗前PET/CT成像和PBPK/PD建模预测治疗后肿瘤体积。
主要发现
- 排除1例前列腺特异性抗原阴性患者后,PSMA阳性肿瘤细胞治疗后6周预测与实测肿瘤体积的相对偏差为1%±40%。
- PSA阳性患者的放射敏感性确定为0.0172±0.0084 Gy⁻¹。
局限性
- 原文报告内部验证显示该方法可行且精度可接受,方法改进和模型外部验证正在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this work was to develop a theranostic method that allows prediction of prostate-specific membrane antigen (PSMA)-positive tumor volume after radioligand therapy (RLT) based on a pretherapeutic PET/CT measurement and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling at the example of RLT using 177Lu-labeled PSMA for imaging and therapy (PSMA I&T). Methods: A recently developed PBPK model for 177Lu-PSMA I&T RLT was extended to account for tumor (exponential) growth and reduction due to irradiation (linear quadratic model). Data from 13 patients with metastatic castration-resistant prostate cancer were retrospectively analyzed. Pharmacokinetic/pharmacodynamic parameters were simultaneously fitted in a Bayesian framework to PET/CT activity concentrations, planar scintigraphy data, and tumor volumes before and after (6 wk) therapy. The method was validated using the leave-one-out Jackknife method. The tumor volume after therapy was predicted on the basis of pretherapy PET/CT imaging and PBPK/PD modeling. Results: The relative deviation of the predicted and measured tumor volume for PSMA-positive tumor cells (6 wk after therapy) was 1% ± 40%, excluding 1 patient (prostate-specific antigen-negative) from the population. The radiosensitivity for the prostate-specific antigen-positive patients was determined to be 0.0172 ± 0.0084 Gy-1Conclusion: To our knowledge, the proposed method is the first attempt to solely use PET/CT and modeling methods to predict the PSMA-positive tumor volume after RLT. Internal validation shows that this is feasible with an acceptable accuracy. Improvement of the method and external validation of the model is ongoing.
引用
- Kletting P, Thieme A, Eberhardt N, et al. Modeling and Predicting Tumor Response in Radioligand Therapy. J Nucl Med. 2018. PMID: 29748236. doi:10.2967/jnumed.118.210377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。